These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1348430)

  • 21. [The dopaminergic hypothesis revisited].
    Guillin O
    Encephale; 2006 Oct; 32(5 Pt 4):S908-11; discussion S912. PubMed ID: 17119503
    [No Abstract]   [Full Text] [Related]  

  • 22. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Lancet; 1992 Jul; 340(8813):199-202. PubMed ID: 1353135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.
    Farde L; Wiesel FA; Nordström AL; Sedvall G
    Psychopharmacology (Berl); 1989; 99 Suppl():S28-31. PubMed ID: 2573104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
    Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
    Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.
    Zumárraga M; González-Torres MA; Arrue A; Dávila R; Dávila W; Inchausti L; Pérez-Cabeza L; Fernández-Rivas A; Bustamante S; Basterreche N; Guimón J
    Neurochem Res; 2011 Aug; 36(8):1336-43. PubMed ID: 21475956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology and treatment of negative symptoms.
    Villeneuve A
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schizophrenia and the D1 receptor: focus on negative symptoms.
    Lynch MR
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):797-832. PubMed ID: 1355300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
    Fux M; Belmaker RH
    Isr J Psychiatry Relat Sci; 1991; 28(1):37-40. PubMed ID: 1830565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.